Literature DB >> 33977307

GAD65 autoimmunity after treatment with nivolumab: a multifocal presentation.

Giorgia Teresa Maniscalco1,2, Anastasia Zekeridou3,4, Lia Allegorico2, Angelo Ranieri1, Massimo Napolitano1, Marianna Pezzella5, Luigi Della Gatta6, Valentino Manzo1, Sergio Ferrari7, Sara Mariotto8.   

Abstract

INTRODUCTION: Neurological disorders are considered rare complications of immune-checkpoint inhibitor. CASE DESCRIPTION: We report a 63-year-old man with recurrence of melanoma who presented epilepsy, limbic encephalitis, cerebellar ataxia, and stiff person syndrome soon after treatment with nivolumab, an immune-checkpoint inhibitor. On autoimmune screening, serum and CSF GAD65 were detected. Significant response to steroids and intravenous immunoglobulins were observed, but cancer recurred after nivolumab discontinuation in parallel with epileptic seizure and worsening of cognitive impairment and the patient died. DISCUSSION: This case expands the spectrum of GAD65-associated conditions induced by immune-checkpoint inhibitor and underlines treatment complexity when both neurological complications and tumour recurrence occur.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Ataxia; Checkpoint inhibitor; Encephalitis; Epilepsy; GAD65; Stiff person syndrome

Mesh:

Substances:

Year:  2021        PMID: 33977307     DOI: 10.1007/s10072-021-05312-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  7 in total

1.  Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Authors:  Mario Sznol; Pier Francesco Ferrucci; David Hogg; Michael B Atkins; Pascal Wolter; Massimo Guidoboni; Celeste Lebbé; John M Kirkwood; Jacob Schachter; Gregory A Daniels; Jessica Hassel; Jonathan Cebon; Winald Gerritsen; Victoria Atkinson; Luc Thomas; John McCaffrey; Derek Power; Dana Walker; Rafia Bhore; Joel Jiang; F Stephen Hodi; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2017-09-15       Impact factor: 44.544

Review 2.  Neurological toxicities associated with immune-checkpoint inhibitors.

Authors:  Mehdi Touat; Daniel Talmasov; Damien Ricard; Dimitri Psimaras
Journal:  Curr Opin Neurol       Date:  2017-12       Impact factor: 5.710

3.  Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.

Authors:  Albert Saiz; Yolanda Blanco; Lidia Sabater; Félix González; Luis Bataller; Roser Casamitjana; Lluis Ramió-Torrentà; Francesc Graus
Journal:  Brain       Date:  2008-08-07       Impact factor: 13.501

4.  Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange.

Authors:  Matthew Chung; Muhammad Jaffer; Neha Verma; Sepideh Mokhtari; Asha Ramsakal; Edwin Peguero
Journal:  J Neurol       Date:  2019-12-13       Impact factor: 4.849

Review 5.  Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2018-09-14       Impact factor: 6.570

6.  Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma.

Authors:  Suma Shah; Anastasie Dunn-Pirio; Matthew Luedke; Joel Morgenlander; Mark Skeen; Christopher Eckstein
Journal:  Case Rep Neurol Med       Date:  2018-07-04

7.  Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.

Authors:  Elia Sechi; Svetomir N Markovic; Andrew McKeon; Divyanshu Dubey; Teerin Liewluck; Vanda A Lennon; A Sebastian Lopez-Chiriboga; Christopher J Klein; Michelle Mauermann; Sean J Pittock; Eoin P Flanagan; Anastasia Zekeridou
Journal:  Neurology       Date:  2020-08-13       Impact factor: 9.910

  7 in total
  4 in total

1.  Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature.

Authors:  Yining Gao; Jie Pan; Dingding Shen; Lisheng Peng; Zhifeng Mao; Chunxia Wang; Huanyu Meng; Qinming Zhou; Sheng Chen
Journal:  Brain Sci       Date:  2022-06-13

2.  Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab.

Authors:  Huanyu Zhou; Xiaoxi Xie; Tianyu Zhang; Menghan Yang; Dong Zhou; Tianhua Yang
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

Review 3.  Paraneoplastic and Other Autoimmune Encephalitides: Antineuronal Antibodies, T Lymphocytes, and Questions of Pathogenesis.

Authors:  John E Greenlee; Noel G Carlson; Justin R Abbatemarco; Ida Herdlevær; Stacey L Clardy; Christian A Vedeler
Journal:  Front Neurol       Date:  2022-01-17       Impact factor: 4.003

Review 4.  Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies.

Authors:  María José Aguilar-Castillo; Pablo Cabezudo-García; Nicolas Lundahl Ciano-Petersen; Guillermina García-Martin; Marta Marín-Gracia; Guillermo Estivill-Torrús; Pedro Jesús Serrano-Castro
Journal:  Biomedicines       Date:  2022-03-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.